Navigation Links
ALung Secures $2.5 Million
Date:10/6/2009

0 per day, Hemolung is expected to reduce hospital costs through its ability to reduce ICU length of stay. Further cost savings are expected to be realized through the elimination of sedation costs and a reduction in adverse outcomes such as ventilator acquired pneumonia (VAP) - estimated at greater than $125,000 per incident. VAP represents the most common and deadly hospital acquired condition (HAC) with approximately 25 percent of all ventilator patients developing the condition. (ref: Society of Critical Care Medicine).

"We are very enthusiastic regarding the positive outcome of our near-term clinical trials," said Mr. Nick Kuhn, Chief Operating Officer of ALung, "The completion of our eight animal studies, as well as our in vitro testing, have resulted in excellent results, indicating that the upcoming Hemolung human clinical trials should yield very positive results."

ALung is moving forward with a five patient "First in Man" trial in India on the Hemolung

System, and a 20 patient pilot trial in Germany. Both trials are expected to begin in the fourth quarter of 2009.

About ALung Technologies

ALung Technologies, Inc. is commercializing artificial lung devices for the treatment of acute and chronic respiratory disorders. The company's Hemolung System, designed to replace or supplement the use of ventilators for patients with acute respiratory failure, is scheduled to begin clinical trials in the fall of 2009. Learn more about ALung and Hemolung at www.alung.com.

SOURCE ALung Technologies, Inc.


'/>"/>
SOURCE ALung Technologies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Aegerion Pharmaceuticals, Inc. adds Peter Garrambone to Board of Directors, Secures Additional Capital for Clinical Trials
2. Alexion Secures U.S. Patent for ALXN6000, a First-In-Class Anti-CD200 Monoclonal Antibody
3. GeoVax Secures $10 Million Financing Commitment
4. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
5. CEL-SCI Secures Manufacturing Facility for Multikine Cancer Drug
6. Blue Shield of California Awards $29.6 Million in Pay-for-Performance Programs in 2009
7. Misonix, Inc. Announces the Sale of Sonora Medical Systems for $8 Million
8. Catalyst Pharmaceutical Partners, Inc. To Raise $3.97 Million In Registered Direct Offering
9. SyntheMed Completes $1.0 Million Equity Placement
10. CVS Caremark Launches Distribution of $3 million in Free Seasonal Flu Shot Vouchers to the Unemployed
11. ThermalTherapeutic Systems Completes $2.75 Million Series A Financing With Originate Ventures
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/13/2014)... Auf seiner am ... veranstalteten F&E-Tagung meldete Astellas Fortschritte im ... Forschungsrahmenprogramms. Die Tagung bot Astellas die Gelegenheit, ... Programme und die Konzernstrategie des Unternehmens zu ... aktuelle Meldungen zu den Astellas-Initiativen in den ...
(Date:7/13/2014)... 13, 2014  Eli Lilly and Company (NYSE: ... its non-clinical study in genetically engineered mice examining ... beta-amyloid antibody N3pG and beta-secretase inhibitor BACE (LY2811376). ... effective in removing clumps of amyloid-beta protein in ... to lead to Alzheimer,s disease (AD) – than ...
(Date:7/11/2014)... LOS ANGELES , July 11, 2014 /PRNewswire-iReach/ ... of e-liquid, a vegetable-glycol solution for use in ... one of the active ingredients in cannabis, cannabidiol ... in personal vaporizer devices, and other vaporizer technology. ... Cannabis naturally contains 483 different compounds ...
Breaking Medicine Technology:Astellas erörtert Pipeline-Fortschritte auf F&E-Tagung 2Astellas erörtert Pipeline-Fortschritte auf F&E-Tagung 3Astellas erörtert Pipeline-Fortschritte auf F&E-Tagung 4New Data Shows Combination Therapy is More Effective than Monotherapy in Removing Beta-Amyloid Plaques from the Brains of Mice 2New Data Shows Combination Therapy is More Effective than Monotherapy in Removing Beta-Amyloid Plaques from the Brains of Mice 3VAPETEK Releases CBD-Infused eLiquid For The Consumer Market 2
(Date:7/13/2014)... NC (PRWEB) July 13, 2014 Carolinas ... its newest location, the Carolinas HealthCare System - Anson ... replaces the aged Anson Community Hospital in Wadesboro. , ... approximately three miles from the previous facility. Situated on ... floorplan that includes an emergency room drop-off, helipad, healing ...
(Date:7/13/2014)... (PRWEB) July 13, 2014 Intraocular Lens ... and Forecast 2013 - 2019 , Intraocular lens (IOL) ... from myopia or cataracts. The lenses are inserted inside ... cataract surgery intraocular lens replaces the focusing power of ... original crystalline lens to deliver the light focusing function ...
(Date:7/13/2014)... Nature Genetics identifies a novel genetic ... eosinophillic esophagitis (EoE), opening up potential new therapeutic ... , EoE is a chronic inflammatory disorder ... allergic hypersensitivity to certain foods and an over-accumulation ... eosinophils (part of the body,s immune system). EoE ...
(Date:7/13/2014)... type-1 diabetes could improve patient care worldwide and ... the device,s inventors at the Stanford University School ... be published online July 13 in Nature ... type-1 diabetes outside hospital settings. The handheld microchips ... mellitus, which are both characterized by high blood-sugar ...
(Date:7/13/2014)... 2014 Chromatography system is a ... various types of biological samples such as air ... mixture into two phase, namely mobile phase and ... run over the stationary phase, followed by the ... provide the separation of mixture. Chromatography system plays ...
Breaking Medicine News(10 mins):Health News:Carolinas HealthCare System - Anson Hospital Now Open 2Health News:Intraocular Lens (IOL) Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 2Health News:Intraocular Lens (IOL) Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 3Health News:Intraocular Lens (IOL) Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 4Health News:Study finds cause of mysterious food allergy, suggests new treatment strategy 2Health News:Study finds cause of mysterious food allergy, suggests new treatment strategy 3Health News:Stanford researchers invent nanotech microchip to diagnose type-1 diabetes 2Health News:Stanford researchers invent nanotech microchip to diagnose type-1 diabetes 3Health News:Stanford researchers invent nanotech microchip to diagnose type-1 diabetes 4Health News:North America Chromatography Systems Market Is Expected to Reach $6593.4 Million by 2018 - New Report by MicroMarket Monitor 2Health News:North America Chromatography Systems Market Is Expected to Reach $6593.4 Million by 2018 - New Report by MicroMarket Monitor 3
... (OTC Bulletin Board: PLCSF) announced today that it expects to ... fourth quarter and year ended December 31, 2008 before the ... to host a conference call to discuss those results at ... be joined via telephone by dialing (866) 356-3377 or (617) ...
... Living Life as Fully as Possible , ALEXANDRIA, Va., ... Organization wants all people to know that hospice delivers ... family caregivers who are coping with life-limiting illness. A ... Presents Legal Quandary," by Greg Bluestein, 03/02/09) carries a ...
... Known for Her Quest to Raise One Million Dollars for ... JACKSONVILLE, Fla., March 3 At 56, Linda Quirk has ... in just under a year. She began her trek ... 2008 and has since gone on to run the Great ...
... Inc. (Pink Sheets: SNDY) is pleased to announce that ... (FDA) Level II Baseline Inspection and received a NAI ... for the FDA to periodically perform unannounced inspections for ... FDA validates the Company,s quality system and its strict ...
... nine children, One in ten adults. , One in ... home , 402 people died due to asthma in 2006, ... People with asthma should have a written asthma action plan but ... telling patients what to do if their asthma gets worse. An ...
... disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are ... to cirrhosis and hepatocellular carcinoma. To date, ... in these conditions and no approved therapeutic ... system overexpression plays a central role in ...
Cached Medicine News:Health News:NHPCO Comments on Misleading Quote in Associated Press Article and Provides Helpful Information 2Health News:56-Year-Old Grandmother Heads to Antarctica to Run Her Seventh Worldwide Marathon in Under a Year 2Health News:56-Year-Old Grandmother Heads to Antarctica to Run Her Seventh Worldwide Marathon in Under a Year 3Health News:Solos Endoscopy, Inc. Successfully Completes FDA Inspection 2Health News:Is telmisartan effective in treating non-alcoholic steatohepatitis? 2Health News:Is telmisartan effective in treating non-alcoholic steatohepatitis? 3
... features a low molecular weight ... viscosity you need to achieve ... small-incision surgery. The sustained viscoelastic ... depth for safe, ample working ...
... CoEase is designed to provide excellent protection ... unique advantage of being closer to an ... This allows CoEase to maintain viscosity ... best of both worlds for superb performance ...
... ophthalmic viscosurgical device is a ... by high molecular weight, high ... It provides excellent space maintenance, ... easily removed. It is available ...
... DigitalCameras permit fundus imaging and documentation ... without any need for eyepieces guarantees ... Image recording and display is an ... the ophthalmoscope principle of modern fundus ...
Medicine Products: